{
  "summary": {
    "total_tests": 7,
    "equivalent_results": 3,
    "different_results": 4,
    "high_significance_differences": 0,
    "medium_significance_differences": 0,
    "low_significance_differences": 0,
    "differences_by_focus": {
      "comutation_patterns": 4
    },
    "differences_by_category": {
      "major_clinical_impact": 4
    }
  },
  "test_results": [
    {
      "test_id": "test_1_comutation_patterns",
      "input_data": {
        "blasts_percentage": 75,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "dnmt3a_npm1_flt3",
        "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.559798",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 75,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "dnmt3a_npm1_flt3",
        "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
      }
    },
    {
      "test_id": "test_2_comutation_patterns",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "tet2_sf3b1_mds",
        "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.559930",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "tet2_sf3b1_mds",
        "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
      }
    },
    {
      "test_id": "test_3_comutation_patterns",
      "input_data": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.559999",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      }
    },
    {
      "test_id": "test_4_comutation_patterns",
      "input_data": {
        "blasts_percentage": 35,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {},
        "pattern_name": "tp53_complex_karyotype",
        "pattern_description": "TP53 mutation with complex karyotype"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.560056",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 35,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {},
        "pattern_name": "tp53_complex_karyotype",
        "pattern_description": "TP53 mutation with complex karyotype"
      }
    },
    {
      "test_id": "test_5_comutation_patterns",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SRSF2": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "srsf2_tet2_cmml_like",
        "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.560108",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SRSF2": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "srsf2_tet2_cmml_like",
        "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
      }
    },
    {
      "test_id": "test_6_comutation_patterns",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "U2AF1": true,
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "pattern_name": "u2af1_dnmt3a_secondary",
        "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
      },
      "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
      "icc_classification": "MDS with excess blasts, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => MDS with excess blasts, therapy related",
        "Final classification => MDS with excess blasts, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
        "icc_classification": "MDS with excess blasts, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.560169",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "U2AF1": true,
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "pattern_name": "u2af1_dnmt3a_secondary",
        "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
      }
    },
    {
      "test_id": "test_7_comutation_patterns",
      "input_data": {
        "blasts_percentage": 14,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "EZH2": true,
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "ezh2_asxl1_high_risk",
        "pattern_description": "EZH2 + ASXL1 high-risk combination"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 14, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T20:05:12.560221",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 14,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "EZH2": true,
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "ezh2_asxl1_high_risk",
        "pattern_description": "EZH2 + ASXL1 high-risk combination"
      }
    }
  ],
  "timestamp": "2025-06-06T20:05:12.560918",
  "total_tests": 7
}